Mehran Farid-Moayer, MD
Sleep Medicine · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
Offices
5 locations · Peninsula Sleep Center Inc · Stanford Health Care
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Farid-Moayer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A66203 · Current
Licensed to practise in California · since 1998 · expires 2028-01-31 · Tehran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$94,734
Medicare paid this office $94,734 for 467 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Sleep study including heart rate, breathing, and sleep time | 265 | $37,546 | $136 |
| Return visit (30+ min) | 145 | $21,645 | $112 |
| New patient visit (45+ min) | 81 | $12,357 | $153 |
| Sleep study in sleep lab (6 years or older) | 11 | $6,363 | $578 |
| Long return visit (40+ min) | 22 | $4,225 | $163 |
See all 10 services
| Sleep study including heart rate, breathing, and sleep time | 265 | $37,546 | $136 |
| Return visit (30+ min) | 145 | $21,645 | $112 |
| New patient visit (45+ min) | 81 | $12,357 | $153 |
| Sleep study in sleep lab (6 years or older) | 11 | $6,363 | $578 |
| Long return visit (40+ min) | 22 | $4,225 | $163 |
| Short return visit (20+ min) | 30 | $2,366 | $74 |
| New patient visit (30+ min) | 18 | $1,579 | $88 |
| Test to determine lung volumes using sensors | 21 | $227 | $11 |
| Test to examine how well the lungs exchange gases | 20 | $160 | $8 |
| Test to measure expiratory airflow and volume | 13 | $96 | $7 |
Who their Medicare patients are
467 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 11% · Women 44% · Also on Medicaid 5% · Health risk score 1.14. At or below the middle of the specialty; the typical sleep medicine clinician is at 1.21.
Conditions among them: High blood pressure 73% · Diabetes 29% · Coronary heart disease 28% · Atrial fibrillation 25% · Chronic kidney disease 24% · Depression 19% · Heart failure 16% · Cancer 15% · COPD 12% · Dementia 6% · Stroke 5%.
The office billed $417,050, Medicare allowed $125,746 and paid $94,734; for 728 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 467 | 728 | 75 | 1.14 | $417,050 | $94,734 |
| 2023 | 333 | 587 | 74 | 1.11 | $297,761 | $71,367 |
| 2022 | 300 | 467 | 74 | 1.08 | $261,703 | $71,166 |
| 2021 | 310 | 473 | 75 | 1.09 | $166,089 | $59,898 |
| 2020 | 425 | 830 | 75 | 1.29 | $259,780 | $96,470 |
| 2019 | 522 | 1,049 | 75 | 1.33 | $390,311 | $131,943 |
| 2018 | 443 | 841 | 74 | 1.28 | $307,803 | $97,119 |
| 2017 | 524 | 1,057 | 73 | 1.30 | $626,328 | $179,523 |
| 2016 | 406 | 847 | 74 | 1.28 | $433,346 | $122,774 |
| 2015 | 433 | 866 | 73 | 1.34 | $690,520 | $191,453 |
| 2014 | 468 | 1,091 | 73 | 1.14 | $816,217 | $229,059 |
| 2013 | 393 | 770 | 73 | 1.20 | $757,584 | $214,950 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Sleep study including heart rate, breathing, and sleep time | 165 | $25,771 | $146 |
| Return visit (30+ min) | 127 | $18,678 | $111 |
| New patient visit (45+ min) | 75 | $10,995 | $147 |
| Long return visit (40+ min) | 19 | $3,793 | $158 |
| New patient visit (30+ min) | 27 | $2,655 | $98 |
| Short return visit (20+ min) | 29 | $2,383 | $74 |
| Test to determine lung volumes using sensors | 21 | $226 | $11 |
| Test to examine how well the lungs exchange gases | 21 | $167 | $8 |
| Test to measure expiratory airflow and volume | 11 | $81 | $7 |
2022: 10 services
| Sleep study including heart rate, breathing, and sleep time | 125 | $20,409 | $153 |
| Return visit (30+ min) | 99 | $14,232 | $119 |
| New patient visit (45+ min) | 54 | $7,626 | $141 |
| Sleep study in sleep lab (6 years or older) | 11 | $7,071 | $643 |
| New patient visit (60+ min) | 35 | $6,989 | $200 |
| Long return visit (40+ min) | 23 | $4,090 | $170 |
| Short return visit (20+ min) | 24 | $1,859 | $74 |
| New patient visit (30+ min) | 14 | $1,160 | $83 |
| Therapy procedure using a positive pressure ventilator | 13 | $811 | $62 |
| Short return visit | 12 | $658 | $55 |
2021: 13 services
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 93 | $19,245 | $203 |
| New patient visit (60+ min) | 43 | $8,503 | $198 |
| Return visit (30+ min) | 56 | $7,549 | $116 |
| Telephone medical discussion with physician, 21-30 minutes | 39 | $4,597 | $100 |
| Long return visit (40+ min) | 18 | $3,801 | $173 |
| New patient visit (45+ min) | 23 | $3,589 | $156 |
| Sleep study including heart rate, breathing, and sleep time | 12 | $2,101 | $175 |
| Telephone medical discussion with physician, 11-20 minutes | 24 | $1,833 | $63 |
| New patient visit (15+ min) | 18 | $1,279 | $71 |
| Short return visit (20+ min) | 15 | $1,245 | $83 |
| Short return visit | 21 | $1,118 | $53 |
| Test to determine lung volumes using sensors | 13 | $144 | $10 |
| Test to examine how well the lungs exchange gases | 14 | $122 | $8 |
2020: 9 services
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 127 | $30,435 | $229 |
| Return visit (30+ min) | 148 | $17,594 | $89 |
| Short return visit (20+ min) | 183 | $15,833 | $69 |
| New patient visit (45+ min) | 56 | $7,744 | $138 |
| Telephone medical discussion with physician, 11-20 minutes | 61 | $5,310 | $73 |
| Long return visit (40+ min) | 30 | $4,694 | $130 |
| Telephone medical discussion with physician, 21-30 minutes | 37 | $4,407 | $105 |
| New patient visit (60+ min) | 16 | $2,681 | $168 |
| New patient visit (30+ min) | 27 | $2,537 | $94 |
2019: 14 services
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 145 | $36,401 | $229 |
| Return visit (30+ min) | 214 | $29,518 | $98 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 19 | $13,203 | $660 |
| New patient visit (45+ min) | 87 | $11,854 | $136 |
| Sleep study in sleep lab (6 years or older) | 18 | $11,458 | $637 |
| Short return visit (20+ min) | 123 | $8,769 | $59 |
| New patient visit (60+ min) | 44 | $8,134 | $185 |
| Long return visit (40+ min) | 44 | $7,939 | $135 |
| New patient visit (30+ min) | 21 | $1,633 | $78 |
| Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | 13 | $934 | $52 |
| Test to determine lung volumes using sensors | 50 | $559 | $11 |
| Test to examine how well the lungs exchange gases | 53 | $438 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $428 | $12 |
| Test to measure expiratory airflow and volume | 17 | $130 | $8 |
2018: 13 services
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 106 | $23,415 | $217 |
| Short return visit (20+ min) | 204 | $17,198 | $60 |
| Sleep study in sleep lab (6 years or older) | 24 | $14,520 | $605 |
| New patient visit (45+ min) | 84 | $10,885 | $130 |
| Return visit (30+ min) | 84 | $9,669 | $90 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 11 | $7,404 | $673 |
| New patient visit (60+ min) | 37 | $6,263 | $169 |
| Therapy procedure using a positive pressure ventilator | 66 | $3,869 | $58 |
| Long return visit (40+ min) | 11 | $1,750 | $135 |
| Test to determine lung volumes using sensors | 30 | $331 | $11 |
| Test to examine how well the lungs exchange gases | 31 | $253 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $165 | $12 |
| Test to measure expiratory airflow and volume | 20 | $150 | $8 |
2017: 12 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 77 | $52,848 | $669 |
| Sleep study in sleep lab (6 years or older) | 70 | $43,181 | $608 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 89 | $20,060 | $218 |
| New patient visit (45+ min) | 119 | $16,774 | $141 |
| Short return visit (20+ min) | 192 | $16,541 | $63 |
| Return visit (30+ min) | 117 | $12,898 | $88 |
| Therapy procedure using a positive pressure ventilator | 122 | $8,553 | $58 |
| New patient visit (60+ min) | 35 | $6,034 | $172 |
| Test to determine lung volumes using sensors | 23 | $254 | $11 |
| Test to examine how well the lungs exchange gases | 26 | $212 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $211 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $140 | $13 |
2016: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 52 | $33,796 | $650 |
| Sleep study in sleep lab (6 years or older) | 50 | $32,042 | $641 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 68 | $14,896 | $216 |
| Short return visit (20+ min) | 144 | $12,526 | $60 |
| New patient visit (45+ min) | 62 | $8,191 | $132 |
| Return visit (30+ min) | 62 | $6,978 | $91 |
| Therapy procedure using a positive pressure ventilator | 83 | $5,294 | $57 |
| Long return visit (40+ min) | 27 | $3,374 | $116 |
| New patient visit (60+ min) | 11 | $2,064 | $188 |
| New patient visit (30+ min) | 16 | $1,521 | $95 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $538 | $19 |
| Test to determine lung volumes using sensors | 45 | $485 | $11 |
| Test to examine how well the lungs exchange gases | 48 | $378 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 27 | $284 | $11 |
| Test to measure expiratory airflow and volume | 21 | $167 | $8 |
2015: 11 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 125 | $85,773 | $660 |
| Sleep study in sleep lab (6 years or older) | 67 | $42,337 | $632 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 67 | $16,283 | $220 |
| Short return visit (20+ min) | 144 | $12,313 | $63 |
| New patient visit (45+ min) | 76 | $11,423 | $150 |
| Return visit (30+ min) | 78 | $8,417 | $85 |
| Therapy procedure using a positive pressure ventilator | 80 | $5,591 | $58 |
| New patient visit (60+ min) | 22 | $3,773 | $171 |
| Long return visit (40+ min) | 12 | $1,790 | $128 |
| Short return visit (20+ min) | 19 | $910 | $46 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $317 | $20 |
2014: 16 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 157 | $110,963 | $660 |
| Sleep study in sleep lab (6 years or older) | 63 | $38,924 | $618 |
| Return visit (30+ min) | 131 | $20,505 | $98 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 67 | $15,728 | $222 |
| Short return visit (20+ min) | 116 | $10,524 | $67 |
| New patient visit (60+ min) | 42 | $7,700 | $183 |
| New patient visit (45+ min) | 47 | $7,005 | $149 |
| Therapy procedure using a positive pressure ventilator | 79 | $5,067 | $60 |
| Extended office or other outpatient service, first hour | 32 | $3,046 | $85 |
| Sleep study including heart rate, breathing, airflow, and effort | 14 | $2,170 | $121 |
| Short return visit (20+ min) | 24 | $1,093 | $46 |
| Short return visit | 12 | $502 | $42 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 19 | $415 | $20 |
| Test to determine lung volumes using sensors | 34 | $366 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 28 | $319 | $11 |
| Test to examine how well the lungs exchange gases | 35 | $279 | $8 |
2013: 15 services
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 142 | $104,535 | $692 |
| Sleep study in sleep lab (6 years or older) | 86 | $57,502 | $661 |
| Return visit (30+ min) | 98 | $15,547 | $94 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 41 | $10,533 | $219 |
| New patient visit (60+ min) | 44 | $8,113 | $184 |
| New patient visit (45+ min) | 30 | $4,190 | $140 |
| Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | 18 | $3,800 | $200 |
| Long return visit (40+ min) | 21 | $2,946 | $128 |
| Short return visit (20+ min) | 27 | $1,852 | $66 |
| Therapy procedure using a positive pressure ventilator | 24 | $1,391 | $53 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $827 | $20 |
| Short return visit (20+ min) | 25 | $760 | $30 |
| Test to determine lung volumes using sensors | 16 | $185 | $12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $161 | $11 |
| Test to examine how well the lungs exchange gases | 15 | $127 | $8 |
Drugs they prescribed that Part D paid
$54,111
Pharmacies billed $54,111 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
246 generic and 57 brand-name prescriptions · $54,111 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Neupro | 23 | $24,040 | $1,045 |
| Sunosi | 11 | $9,768 | $888 |
| Modafinil | 29 | $5,771 | $199 |
| Doxepin | 16 | $2,789 | $174 |
| Pramipexole Dihydrochloride | 16 | $500 | $31 |
See all 11 drugs
| Neupro | 23 | $24,040 | $1,045 |
| Sunosi | 11 | $9,768 | $888 |
| Modafinil | 29 | $5,771 | $199 |
| Doxepin | 16 | $2,789 | $174 |
| Pramipexole Dihydrochloride | 16 | $500 | $31 |
| Clonazepam | 42 | $475 | $11 |
| Gabapentin | 42 | $449 | $11 |
| Zolpidem | 40 | $238 | $6 |
| Zolpidem Tartrate Er | 15 | $193 | $13 |
| Mirtazapine | 11 | $136 | $12 |
| Lorazepam | 13 | $75 | $6 |
Year by year
| 2024 | 303 | 54 | None | 19% | $54,111 |
| 2023 | 304 | 60 | None | None | $64,393 |
| 2022 | 293 | 56 | 0% (0) | 24% | $47,410 |
| 2021 | 164 | 41 | None | 29% | $33,562 |
| 2020 | 234 | 48 | None | 28% | $29,709 |
| 2019 | 247 | 55 | None | 25% | $31,479 |
| 2018 | 223 | 63 | None | 22% | $23,039 |
| 2017 | 247 | 55 | 0% (0) | 33% | $41,943 |
| 2016 | 305 | 60 | 0% (0) | 32% | $51,505 |
| 2015 | 271 | 61 | None | 26% | $27,028 |
| 2014 | 283 | 60 | 0% (0) | 30% | $31,397 |
| 2013 | 259 | 48 | 0% (0) | 34% | $27,656 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Neupro | 19 | $21,262 | $1,119 |
| Sunosi | 13 | $16,937 | $1,303 |
| Dayvigo | 15 | $6,679 | $445 |
| Doxepin | 16 | $4,343 | $271 |
| Modafinil | 31 | $2,746 | $89 |
| Gabapentin | 46 | $864 | $19 |
| Pramipexole Dihydrochloride | 15 | $725 | $48 |
| Mirtazapine | 21 | $275 | $13 |
| Zolpidem | 32 | $210 | $7 |
| Zolpidem Tartrate Er | 13 | $96 | $7 |
| Clonazepam | 11 | $49 | $4 |
2022: 11 drugs
| Sunosi | 12 | $19,364 | $1,614 |
| Neupro | 18 | $14,006 | $778 |
| Modafinil | 21 | $1,910 | $91 |
| Doxepin | 11 | $1,381 | $126 |
| Gabapentin | 52 | $500 | $10 |
| Clonazepam | 28 | $264 | $9 |
| Mirtazapine | 18 | $184 | $10 |
| Zolpidem Tartrate Er | 15 | $167 | $11 |
| Zolpidem | 24 | $127 | $5 |
| Temazepam | 13 | $125 | $10 |
| Lorazepam | 11 | $39 | $4 |
2021: 7 drugs
| Neupro | 12 | $10,191 | $849 |
| Spiriva Respimat | 15 | $7,104 | $474 |
| Gabapentin | 30 | $738 | $25 |
| Pramipexole Dihydrochloride | 12 | $413 | $34 |
| Clonazepam | 11 | $191 | $17 |
| Zaleplon | 11 | $156 | $14 |
| Mirtazapine | 12 | $111 | $9 |
2020: 5 drugs
| Anoro Ellipta | 26 | $11,575 | $445 |
| Spiriva Respimat | 14 | $6,322 | $452 |
| Clonazepam | 34 | $605 | $18 |
| Gabapentin | 24 | $360 | $15 |
| Zolpidem | 20 | $231 | $12 |
2019: 7 drugs
| Anoro Ellipta | 21 | $9,193 | $438 |
| Gabapentin | 28 | $425 | $15 |
| Doxepin | 19 | $351 | $18 |
| Clonazepam | 30 | $274 | $9 |
| Zolpidem | 13 | $119 | $9 |
| Alprazolam | 15 | $96 | $6 |
| Lorazepam | 13 | $29 | $2 |
2018: 4 drugs
| Clonazepam | 34 | $200 | $6 |
| Fluticasone Propionate | 14 | $159 | $11 |
| Gabapentin | 16 | $133 | $8 |
| Alprazolam | 14 | $70 | $5 |
2017: 9 drugs
| Ambien | 12 | $7,816 | $651 |
| Doxepin | 14 | $221 | $16 |
| Gabapentin | 13 | $184 | $14 |
| Venlafaxine Hcl Er | 14 | $181 | $13 |
| Clonazepam | 39 | $170 | $4 |
| Montelukast | 11 | $159 | $14 |
| Zolpidem | 17 | $126 | $7 |
| Fluticasone Propionate | 12 | $100 | $8 |
| Alprazolam | 12 | $17 | $1 |
2016: 11 drugs
| Spiriva | 12 | $4,697 | $391 |
| Anoro Ellipta | 11 | $3,498 | $318 |
| Advair Diskus | 11 | $3,019 | $274 |
| Modafinil | 13 | $2,522 | $194 |
| Proair Respiclick | 11 | $557 | $51 |
| Clonazepam | 50 | $330 | $7 |
| Gabapentin | 19 | $299 | $16 |
| Montelukast | 11 | $139 | $13 |
| Venlafaxine Hcl Er | 15 | $129 | $9 |
| Alprazolam | 21 | $108 | $5 |
| Zolpidem | 20 | $69 | $3 |
2015: 7 drugs
| Modafinil | 19 | $6,874 | $362 |
| Spiriva | 12 | $3,800 | $317 |
| Clonazepam | 42 | $438 | $10 |
| Fluticasone Propionate | 36 | $286 | $8 |
| Gabapentin | 23 | $285 | $12 |
| Montelukast | 14 | $170 | $12 |
| Zolpidem | 13 | $74 | $6 |
2014: 9 drugs
| Modafinil | 14 | $7,145 | $510 |
| Spiriva | 13 | $4,320 | $332 |
| Ambien Cr | 13 | $4,265 | $328 |
| Flovent Hfa | 13 | $2,245 | $173 |
| Fluticasone Propionate | 35 | $554 | $16 |
| Gabapentin | 33 | $508 | $15 |
| Ropinirole | 16 | $477 | $30 |
| Clonazepam | 44 | $295 | $7 |
| Zolpidem | 23 | $142 | $6 |
2013: 11 drugs
| Ambien Cr | 12 | $3,201 | $267 |
| Spiriva | 11 | $3,040 | $276 |
| Nasonex | 12 | $1,646 | $137 |
| Flovent Diskus | 11 | $1,311 | $119 |
| Ropinirole | 11 | $665 | $60 |
| Gabapentin | 31 | $654 | $21 |
| Proair Hfa | 12 | $607 | $51 |
| Fluticasone Propionate | 21 | $597 | $28 |
| Zaleplon | 13 | $389 | $30 |
| Zolpidem | 31 | $184 | $6 |
| Clonazepam | 27 | $170 | $6 |
Money from drug and device companies
$23 in 2025
| 2025 | 1 | 1 | None | $23 |
| 2024 | 1 | 1 | None | $26 |
| 2023 | 1 | 1 | None | $27 |
| 2021 | 1 | 1 | None | $23 |
| 2020 | 1 | 1 | None | $14 |
| 2019 | 15 | 29 | None | $552 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Zepbound | $23 | 1 payment
|
See the published payment
| Lilly USA | Meals · 2025-03-24 | Zepbound | $23 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $26
| Inspire Medical Systems | Inspire | $26 | 1 payment
|
2023: $27
| Jazz Pharmaceuticals | Xywav | $27 | 1 payment
|
2021: $23
| Eisai | Dayvigo | $23 | 1 payment
|
2020: $14
| Sunovion Pharmaceuticals | Lonhala Magnair | $14 | 1 payment
|
2019: $552
| Jazz Pharmaceuticals | Xyrem | $109 | 7 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $84 | 4 payments
|
| Mylan Specialty L.P. | Yupelri | $57 | 3 payments
|
| Sunovion Pharmaceuticals | Lonhala Magnair | $46 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $42 | 2 payments
|
| Resmed | Aircurve | $40 | 1 payment
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $26 | 1 payment
|
| Actelion Pharmaceuticals US | Uptravi | $25 | 1 payment
|
| Teva Pharmaceuticals USA | Cinqair | $22 | 1 payment
|
| Electromed | Smartvest | $20 | 2 payments
|
| Genentech USA | Xolair | $19 | 1 payment
|
| Merck Sharp & Dohme | Zerbaxa | $19 | 1 payment
|
| Chiesi USA | Cleviprex | $17 | 1 payment
|
| Philips Electronics North America | Trilogy 100 | $15 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184690984
- Licence
- CA A66203California A66203: Current · expires 2028-01-31
- Group
- Peninsula Sleep Center Inc · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RS0012X (207RS0012X); Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 1720 El Camino Real Ste 105, Burlingame, CA, 94010
- NPI first listed
- 2006-02-23
- NPI last updated
- 2025-11-03
- NPI record certified
- 2025-11-03
This is when the NPI record was last certified, not a medical board exam.